Key result
Cancer surgery <12 months post-PCI is linked to ~23% higher mortality and more major complications.
Why the study?
Noncardiac surgery shortly after PCI increases perioperative ischemic events, but delaying cancer surgery may worsen oncologic staging and recurrence.
Does cancer surgery <12 months after PCI affect cardiovascular and oncological outcomes compared to surgery ≥12 months after PCI in patients with early-stage cancer?
Cohort (n=3,621)
Does cancer surgery <12 months after PCI affect cardiovascular and oncological outcomes compared to surgery ≥12 months after PCI in patients with early-stage cancer?
Performing cancer surgery within 12 months of PCI increases cardiovascular and bleeding risks, but delaying surgery increases the risk of cancer recurrence, highlighting the need for personalized timing.
Individualized post-PCI cancer surgery timing decisions remain essential; this observational association leaves optimal interval unresolved.
BACKGROUND: Patients who undergo noncardiac surgery shortly after percutaneous coronary intervention (PCI) experience higher rates of perioperative ischemic events, but delaying surgery may affect disease staging and influence cancer recurrence. We aimed to evaluate the association between time from PCI to cancer surgery and cardiovascular and oncologic outcomes in patients with early-stage cancer. METHODS AND RESULTS: We included patients with early-stage cancer with a history of PCI who underwent cancer surgery (N=3621). The patients were divided into 2 groups based on the time between the dates of PCI and cancer surgery (<12 and ≥12 months). We also grouped patients who underwent early surgery and late surgery, defined as patients who underwent surgery ≥1 and <1 month after cancer diagnosis. Outcomes included bleeding, spontaneous myocardial infarction, repeat revascularization, cancer recurrence, and death. The time from PCI to cancer surgery <12 months group had higher bleeding (hazard ratio [HR], 1.30 [95% CI, 1.18-1.32]), spontaneous myocardial infarction (HR,1.96 [95% CI, 1.32-2.92]), cancer recurrence (HR, 1.26 [95% CI, 1.01-1.56]), and mortality (HR, 1.23 [95% CI, 1.04-1.44]) compared with the ≥12 months group. Among the time from PCI to cancer surgery <12 months group, the early-surgery group had lower cancer recurrence risk than those who underwent late surgery (HR, 0.70 [95% CI, 0.49-0.99]) without differences in bleeding and cardiac outcome. CONCLUSIONS: Although patients who undergo surgery within 12 months of PCI have higher risks of bleeding and cardiovascular events, delaying surgery may increase the risk of cancer recurrence. Therefore, the timing of surgery should be a personalized decision, weighing the risks of cardiovascular complications against the potential oncologic outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT06357000.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2025) conducted a cohort in Early-stage cancer with a history of percutaneous coronary intervention (n=3,621). Cancer surgery <12 months after PCI vs. Cancer surgery ≥12 months after PCI was evaluated on Mortality (HR 1.23, 95% CI 1.04-1.44). Cancer surgery <12 months after PCI was associated with higher risks of bleeding, spontaneous myocardial infarction, cancer recurrence, and mortality (HR 1.23; 95% CI 1.04-1.44) compared with ≥12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: